TY - JOUR
T1 - Myc matters in HIV-associated lymphoma
AU - Witzig, Thomas E.
N1 - Publisher Copyright:
© 2020 by The American Society of Hematology
PY - 2020/9/10
Y1 - 2020/9/10
N2 - In this issue of Blood, Ramos et al present the results of a randomized phase 2 trial that tested the addition of the oral histone deacetylase (HDAC) inhibitor vorinostat to standard rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH) for patients with HIV-associated diffuse large B-cell lymphoma (DLBCL). Although it was solidly based on preclinical data supporting the concept that an HDAC inhibitor would add efficacy in tumors that often harbor Epstein-Barr virus in the setting of HIV infection, it did not translate into a better result in the clinic, at least with this HDAC inhibitor combined with the R-EPOCH backbone. The complete remission (CR) rates with R-EPOCH (74%) vs R-EPOCH with vorinostat (68%) (P 5.72) and the overall survival (OS) and event-free survival (EFS) rates were similar between arms.1
AB - In this issue of Blood, Ramos et al present the results of a randomized phase 2 trial that tested the addition of the oral histone deacetylase (HDAC) inhibitor vorinostat to standard rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH) for patients with HIV-associated diffuse large B-cell lymphoma (DLBCL). Although it was solidly based on preclinical data supporting the concept that an HDAC inhibitor would add efficacy in tumors that often harbor Epstein-Barr virus in the setting of HIV infection, it did not translate into a better result in the clinic, at least with this HDAC inhibitor combined with the R-EPOCH backbone. The complete remission (CR) rates with R-EPOCH (74%) vs R-EPOCH with vorinostat (68%) (P 5.72) and the overall survival (OS) and event-free survival (EFS) rates were similar between arms.1
UR - http://www.scopus.com/inward/record.url?scp=85091473023&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091473023&partnerID=8YFLogxK
U2 - 10.1182/blood.2020006651
DO - 10.1182/blood.2020006651
M3 - Review article
C2 - 32957115
AN - SCOPUS:85091473023
VL - 136
SP - 1217
EP - 1218
JO - Blood
JF - Blood
SN - 0006-4971
IS - 11
ER -